Mydecine Innovations Group Announces Admission to Trading on the
AQSE Growth Market in London, UK
Mydecine Innovations Group, Inc. (“Mydecine” or the
“Company”) (NEO:MYCO) (AQSE: MYIG) (OTC: MYCOF) (FSE:
0NFA), a biotechnology company engineering the next wave
of innovative medications and treatment protocols to directly
address mental health with a particular emphasis on addiction and
PTSD, announces that it has completed its admission to the Access
segment of the AQSE Growth Market (“
AQSE”) and
that trading commenced at 8:00 A.M. GMT on Tuesday, 10 October 2023
("
Admission") under the ticker "MYIG".
Company Highlights:
- Mydecine Innovations Group Inc. is
an emerging biotech and life sciences company dedicated to
developing and commercializing innovative solutions for treating
mental health problems and enhancing wellbeing.
- The Companies various families of
Novel 2nd generation molecules are showing significant improvements
over the first generation of psychedelic treatments. The Company
has taken the approach that, in order to have a truly successful
drug that is accessible by all, numerous modifications need to be
made to the first generation MDMA or Psilocybin molecules, most
notably shortening the half-life while keeping the experience
integrity intact.
- The Company is currently working
with its pre-clinical team at the University of Alberta to work
these molecules through the Investigational New Drug enabling stage
with the intent to put them into human clinical studies expected to
commence in 2024.
- The Company has a comprehensive
intellectual property strategy covering novel molecules, drug
formulations, delivery mechanisms, and methods of production. The
Company believes this covers all described drug development
activities in our named pipeline and clinical trials. The Company
has filed these applications both in the United States and through
the Patent Cooperation Treaty (PCT) for protection in all
jurisdictions in which the Company does business.
Management Commentary:
Josh Bartch, CEO of the Company stated, “We are
incredibly excited to list our securities for trading in the UK on
the AQSE Growth Market. We believe Mydecine is at a pivotal phase
in its development and look forward to increased exposure to UK and
European investors alike”.
The Company will have a dual listing with its
common shares fully fungible through a CREST Depositary Interest
("CDI"). The CDIs will carry the same ISIN as the Common Shares
listed in Canada on NEO. The issued share capital of Mydecine
comprises 45,207,458 common shares.
Sector Classification:The
Company is classified as a Healthcare company on the Access Segment
of the Aquis Stock Exchange.
This announcement, together with any documents
incorporated by reference, shall be deemed to constitute an
admission document for the purposes of the AQSE Growth Market Rules
for Issuers – Access. It has not been approved or reviewed by the
Aquis Stock Exchange or the Financial Conduct Authority.
The Directors are of the opinion, having made
due and careful enquiry, that the working capital available to the
Company is sufficient for a period of at least twelve months
following admission.
The Directors of Mydecine take responsibility
for this announcement.
This announcement contains inside information
for the purposes of Article 7 of the Market Abuse Regulation (EU)
596/2014 as it forms part of UK domestic law by virtue of the
European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in
accordance with the Company's obligations under Article 17 of
MAR.
Learn more
at https://www.mydecine.com.
For more information, please contact:
Mydecine Innovations Group, Inc.Media
Contact pr@mydecineinc.comInvestor
Relations
investorrelations@mydecineinc.com
On behalf of the Board of DirectorsJosh Bartch,
Chief Executive Officercontact@mydecineinc.com
AQSE Corporate AdvisorNovum
Securities
Limited Tel:
+44 (0)207 399 9400David Coffman/ George Duxberry
For further information about Mydecine
Innovations Group, Inc., please visit the Company’s profile on
SEDAR+ at www.sedarplus.com or the Company’s website
at www.mydecine.com.
About Mydecine Innovations Group Inc.
Mydecine Innovations Group is a publicly traded,
pre-revenue biopharmaceutical company that began operations in
North America and Europe in early 2020. Mydecine was founded to
increase physicians' access to serotonin-modulating medicine.
Recent research has demonstrated the therapeutic potential of
psychedelic substances such as psilocybin and MDMA for treating
intractable conditions such as pain, anxiety, depression,
addiction, and PTSD, along with neurodegenerative disorders.
Mydecine believes these compounds can be safer, more effective, and
more accessible for patients and medical professionals through
modern drug chemistry paired with artificial intelligence (AI).
Mydecine is developing innovative medications for target
indications with high mortality rates that have lacked innovation
for decades and are controlled by dominant corporations. Mydecine
developed several prodrug families, beginning with a
psilocybin-derived smoking cessation drug undergoing a NIDA-funded
trial at Johns Hopkins University. Mydecine is also developing
MYCO-006—short-acting chemical analogs derived from MDMA for
treating various conditions, including anxiety and pain. Mydecine
utilises cutting-edge artificial intelligence (AI) and pharma
research infrastructure at the University of Alberta to develop and
manufacture new medications to make them affordable and accessible
to the general public upon Health Canada and FDA approval. The
Mydecine team is enthusiastic about its mission and is dedicated to
creating a positive difference in the lives of others.
Directors:
Josh Bartch, Chief Executive Officer and
Chairman
Josh Bartch is Director, Chief Executive
Officer, and Chairman of Mydecine Innovations Group (MIG). His
entrepreneurial career commenced in 2009 when he cofounded
AudioTranscriptionist.com and founded the Denver-based dispensary,
Doctors Orders. Following these ventures, Josh founded a boutique
investment firm that operated throughout the U.S. and Canadian
markets. In 2014, he co-founded Cannabase.io, the U.S.’s most
significant legal and sophisticated cannabis wholesale platform. He
made successful exits from AudioTranscriptionist.com, Doctor’s
Orders, and Cannabase.io.
Robert Roscow, Chief Science
Officer
Robert is Chief Science Officer of Mydecine
bringing his diverse background in biology, biotechnology, policy
and intellectual property to innovation in the mycology space.
Robert’s substantial expertise includes genetic engineering,
molecular biology, bioinformatics, plant breeding and tissue
culture, photomicroscopy, unicellular microinjection, fish
husbandry and breeding colony maintenance andtransfection.Following
academic work studying the genetic dynamics of cellular patterning,
Robert applied his advanced knowledge to cannabis plant
enhancement. He joined ebbu in 2015, where he created IP related to
the commercial optimisation of Cannabis sativa, industrial hemp and
hops, resulting in three pending US patents.In 2019 Rob oversaw the
design, build and staffing of a plant analytical chemistry
laboratory in Ontario, Canada, for Canopy Growth Corporation where
he was Lead Director of Genetic Research. He also participated in
the Colorado Hemp Advancement & Management Plan Initiative
Cannabis Industry as an industry stakeholder in 2019.
Neil Stevenson-Moore, Non-Executive
Director
Neil is an experienced executive and thought
leader in the technology community. He has a track record of
driving growth, success and innovation and has worked in both
corporate and entrepreneurial environments. For the past 15 years
he has founded, led, and advised companies in consumer focused and
medical tech industries including House of Kibaa, SportNinja,
Farfetch and StylePixi He has successfully raised tens of millions
of dollars from private investors, community partners, and
government organisations. Neil holds a Bachelor of International
Politics from Princeton University and has additional coaching
certifications. He is fluent in French and proficient in
Spanish.
Forward-looking Information
This news release contains forward-looking
information about Canadian securities laws regarding the Company
and its business. It relates to future events or performance and
reflects management’s expectations and assumptions. Often but not
always, forward-looking information can be identified by the use of
words such as “expect,” “intends,” “anticipated,” “believes,” or
variations (including negative variations) of such words and
phrases or by stating that specific actions, events, or results
“may,” "could," "would,” or “will” be taken, occur, or be
achieved.
Such forward-looking statements reflect
management’s beliefs and are based on assumptions and information
currently available to the Company. Readers are cautioned that
these forward-looking statements are neither promises nor
guarantees and are subject to risks and uncertainties that may
cause future results to differ materially from those expected,
including, without limitation, risks regarding the COVID-19
pandemic, the availability and continuity of financing, the ability
of the Company to protect and enforce its intellectual property
adequately, the Company's ability to bring its products to
commercial production, the continued growth of the global adaptive
pathway medicine, natural health products, and digital health
industries, and the risks presented by the highly regulated and
competitive market concerning the development, production, sale,
and use of the Company's products. Although the Company has
attempted to identify important factors that could cause actual
results to differ materially from those contained in
forward-looking information, other factors may cause effects not to
be as anticipated, estimated, or intended. There can be no
assurance that such information will be accurate, as actual results
and future events could differ materially from those anticipated.
These forward-looking statements are made as of the date hereof.
The Company is not obligated to update or revise them to reflect
new events or circumstances as required under applicable securities
legislation.
This news release shall not constitute
an offer to sell or the solicitation of an offer to buy nor shall
there be any sale of the securities in any State in which such
offer, solicitation or sale would be unlawful. The securities being
offered have not been, nor will they be, registered under the
United States Securities Act of 1933, as amended, and may not be
offered or sold in the United States absent registration or an
applicable exemption from the registration requirements of the
United States Securities Act of 1933, as amended, and applicable
state securities laws.
MYDECINE INNOVATIONS GROUP, INC.Suite 810–789
West Pender Street, Vancouver, British Columbia, V6C 1H2 T:
604-687-2038
Mydecine Innovations (AQSE:MYIG)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Mydecine Innovations (AQSE:MYIG)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024